Who is sponsoring NCT03557424?

NCT03557424 is sponsored by Heilpflanzenwohl AG.

What drugs are being tested in NCT03557424?

Interventions in NCT03557424: Polyglucosamine Glucomannan normal dose (Verum), Polyglucosamine Glucomannan high dose (Verum), Placebo Comparator: Placebo.

What condition does NCT03557424 study?

NCT03557424 studies Overweight and Obesity, Weight Loss, Efficacy, Self.

Is NCT03557424 still recruiting?

NCT03557424 is currently completed. Last updated 15 June 2018.

Last reviewed 2018-06-15 · How we verify

NCT03557424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BEFORE Study, Efficacy of Refigura

Completed Phase 4 Last updated 15 June 2018

What this trial tests

Phase 4 trial testing Polyglucosamine Glucomannan normal dose (Verum) in Overweight and Obesity in 165 participants. Completed in 16 April 2018.

Timeline

26 April 2017

Primary endpoint
16 April 2018

16 April 2018

Quick facts

Lead sponsor	Heilpflanzenwohl AG
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	165
Start date	26 April 2017
Primary completion	16 April 2018
Estimated completion	16 April 2018
Sites	1 location across Germany

Drugs / interventions tested

Polyglucosamine Glucomannan normal dose (Verum) — full drug profile →
Polyglucosamine Glucomannan high dose (Verum) — full drug profile →
Placebo Comparator: Placebo

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →
Weight Loss — all drugs for Weight Loss →
Efficacy, Self — all drugs for Efficacy, Self →

Sponsor

Heilpflanzenwohl AG — full company profile →

Who can join

Adults 20 to 50, any sex, with Overweight and Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BEFORE study ((B) EFficacy Of REfigura) is designed to demonstrate the efficacy of REFIGURA®. It is a double-blind, randomized, monocentric study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03557424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Heilpflanzenwohl AG
Last refreshed: 15 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03557424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing